Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On February 10, Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy rating. The firm cited encouraging Phase 2 data for brepocitinib in cutaneous sarcoidosis, an inflammatory condition affecting the skin. The drug’s growth potential prompted the firm to integrate revenue projections into its financial model.

H.C. Wainwright also raised the firm’s price target on Roivant Sciences to $33 from $26 and kept a Buy rating. The firm characterized the Phase 2 data for brepocitinib in cutaneous sarcoidosis reported last week as impressive and added this indication to its valuation model.

A day before, Bank of America raised the firm’s price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $26 from $22 with a Neutral rating. The firm noted that the FQ3 2026 results were in line and highlighted the positive Phase 2 topline results of brepocitinib in cutaneous sarcoidosis, with the higher target reflecting an increased sales forecast for brepocitinib based on these findings.

Pixabay/Public domain

Roivant Sciences Ltd. (NASDAQ:ROIV) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes medicines and technologies.

While we acknowledge the potential of ROIV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.